Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma

Jae Kyeom Sim, Sang Mi Chung, Jong Hyun Choi, Jee Youn Oh, Seung Heon Lee, Je Hyeong Kim, Kyung-Hoon Min, Gyu Young Hur, Jae Jeong Shim, Kyung Ho Kang, Bong Kyung Shin, Ju-Han Lee, Sung Yong Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes. Results: The median age was 69.5 years. Twenty-three patients (88%) were male. Twenty-four patients (92%) were smokers. The median time from symptom onset to diagnosis was one month. Eighteen patients (69%) were diagnosed at an advanced stage. Pleomorphic carcinoma was the most common subtype, and epidermal growth factor receptor (EGFR) mutation was positive in two of 11 patients. Among 13 patients tested for programmed death ligand 1 (PD-L1) immunohis-tochemistry assay, eight showed high expression of PD-L1. The median overall survival (OS) of all patients was 9.5 months. In total, 12 patients were treated with chemotherapy: nine with platinum-based doublet therapy, two with tyrosine kinase inhibitor, and one with docetaxel. Seven patients showed partial response or stable disease. The median OS and progression-free survival of patients who received chemotherapy were 8.7 and 2.8 months, respectively. Conclusions: PSC was more common in males, smokers, and the elderly, with worse prognosis than ordinary NSCLC; chemotherapy response was favorable, and EGFR mutation status and PD-L1 expression may offer more therapeutic options.

Original languageEnglish
Pages (from-to)737-744
Number of pages8
JournalKorean Journal of Internal Medicine
Volume33
Issue number4
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Carcinoma
Lung
docetaxel
Ligands
Epidermal Growth Factor Receptor
Drug Therapy
Non-Small Cell Lung Carcinoma
Mutation
Survival
Giant Cells
Platinum
Protein-Tyrosine Kinases
Disease-Free Survival
Medical Records
Therapeutics

Keywords

  • Epidermal growth factor
  • Programmed death ligand 1
  • Pulmonary sarcomatoid carcinoma
  • Receptor
  • Treatment outcome

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. / Sim, Jae Kyeom; Chung, Sang Mi; Choi, Jong Hyun; Oh, Jee Youn; Lee, Seung Heon; Kim, Je Hyeong; Min, Kyung-Hoon; Hur, Gyu Young; Shim, Jae Jeong; Kang, Kyung Ho; Shin, Bong Kyung; Lee, Ju-Han; Lee, Sung Yong.

In: Korean Journal of Internal Medicine, Vol. 33, No. 4, 01.07.2018, p. 737-744.

Research output: Contribution to journalArticle

@article{a86178109a0444d385a7d84a9bb1e7ca,
title = "Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma",
abstract = "Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes. Results: The median age was 69.5 years. Twenty-three patients (88{\%}) were male. Twenty-four patients (92{\%}) were smokers. The median time from symptom onset to diagnosis was one month. Eighteen patients (69{\%}) were diagnosed at an advanced stage. Pleomorphic carcinoma was the most common subtype, and epidermal growth factor receptor (EGFR) mutation was positive in two of 11 patients. Among 13 patients tested for programmed death ligand 1 (PD-L1) immunohis-tochemistry assay, eight showed high expression of PD-L1. The median overall survival (OS) of all patients was 9.5 months. In total, 12 patients were treated with chemotherapy: nine with platinum-based doublet therapy, two with tyrosine kinase inhibitor, and one with docetaxel. Seven patients showed partial response or stable disease. The median OS and progression-free survival of patients who received chemotherapy were 8.7 and 2.8 months, respectively. Conclusions: PSC was more common in males, smokers, and the elderly, with worse prognosis than ordinary NSCLC; chemotherapy response was favorable, and EGFR mutation status and PD-L1 expression may offer more therapeutic options.",
keywords = "Epidermal growth factor, Programmed death ligand 1, Pulmonary sarcomatoid carcinoma, Receptor, Treatment outcome",
author = "Sim, {Jae Kyeom} and Chung, {Sang Mi} and Choi, {Jong Hyun} and Oh, {Jee Youn} and Lee, {Seung Heon} and Kim, {Je Hyeong} and Kyung-Hoon Min and Hur, {Gyu Young} and Shim, {Jae Jeong} and Kang, {Kyung Ho} and Shin, {Bong Kyung} and Ju-Han Lee and Lee, {Sung Yong}",
year = "2018",
month = "7",
day = "1",
doi = "10.3904/kjim.2017.245",
language = "English",
volume = "33",
pages = "737--744",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "4",

}

TY - JOUR

T1 - Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma

AU - Sim, Jae Kyeom

AU - Chung, Sang Mi

AU - Choi, Jong Hyun

AU - Oh, Jee Youn

AU - Lee, Seung Heon

AU - Kim, Je Hyeong

AU - Min, Kyung-Hoon

AU - Hur, Gyu Young

AU - Shim, Jae Jeong

AU - Kang, Kyung Ho

AU - Shin, Bong Kyung

AU - Lee, Ju-Han

AU - Lee, Sung Yong

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes. Results: The median age was 69.5 years. Twenty-three patients (88%) were male. Twenty-four patients (92%) were smokers. The median time from symptom onset to diagnosis was one month. Eighteen patients (69%) were diagnosed at an advanced stage. Pleomorphic carcinoma was the most common subtype, and epidermal growth factor receptor (EGFR) mutation was positive in two of 11 patients. Among 13 patients tested for programmed death ligand 1 (PD-L1) immunohis-tochemistry assay, eight showed high expression of PD-L1. The median overall survival (OS) of all patients was 9.5 months. In total, 12 patients were treated with chemotherapy: nine with platinum-based doublet therapy, two with tyrosine kinase inhibitor, and one with docetaxel. Seven patients showed partial response or stable disease. The median OS and progression-free survival of patients who received chemotherapy were 8.7 and 2.8 months, respectively. Conclusions: PSC was more common in males, smokers, and the elderly, with worse prognosis than ordinary NSCLC; chemotherapy response was favorable, and EGFR mutation status and PD-L1 expression may offer more therapeutic options.

AB - Background/Aims: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small cell lung cancer (NSCLC) that contains components of spindle or giant cells. Owing to its low prevalence, there are insufficient data regarding its clinical features, therapeutic strategies and prognosis. Methods: The medical records of 26 patients diagnosed with PSC from January 2009 to June 2015 were reviewed and analyzed for clinicopathological characteristics, treatment modality, and outcomes. Results: The median age was 69.5 years. Twenty-three patients (88%) were male. Twenty-four patients (92%) were smokers. The median time from symptom onset to diagnosis was one month. Eighteen patients (69%) were diagnosed at an advanced stage. Pleomorphic carcinoma was the most common subtype, and epidermal growth factor receptor (EGFR) mutation was positive in two of 11 patients. Among 13 patients tested for programmed death ligand 1 (PD-L1) immunohis-tochemistry assay, eight showed high expression of PD-L1. The median overall survival (OS) of all patients was 9.5 months. In total, 12 patients were treated with chemotherapy: nine with platinum-based doublet therapy, two with tyrosine kinase inhibitor, and one with docetaxel. Seven patients showed partial response or stable disease. The median OS and progression-free survival of patients who received chemotherapy were 8.7 and 2.8 months, respectively. Conclusions: PSC was more common in males, smokers, and the elderly, with worse prognosis than ordinary NSCLC; chemotherapy response was favorable, and EGFR mutation status and PD-L1 expression may offer more therapeutic options.

KW - Epidermal growth factor

KW - Programmed death ligand 1

KW - Pulmonary sarcomatoid carcinoma

KW - Receptor

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85048454132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048454132&partnerID=8YFLogxK

U2 - 10.3904/kjim.2017.245

DO - 10.3904/kjim.2017.245

M3 - Article

C2 - 29458244

AN - SCOPUS:85048454132

VL - 33

SP - 737

EP - 744

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 4

ER -